Required fields are marked with *

Verification code

SARS-CoV

CAS No. Product Name Inquiry
2761367-25-1
Antiviral agent 25
2761911-40-2
SARS-CoV-2-IN-16
SARS-CoV-2-IN-16 (Compound 12) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-16 exhibits potent anti-viral activity with the EC50 of 3.69 μM. SARS-CoV-2-IN-16 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-16 is a potent NPro ligand.
2761911-44-6
SARS-CoV-2-IN-17
SARS-CoV-2-IN-17 (Compound 16) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-17 exhibits potent anti-viral activity with the EC50 of 2.18 μM. SARS-CoV-2-IN-17 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-17 is a potent NPro ligand.
2763495-65-2
PB49673382
2763596-72-9
Olgotrelvir Sodium
2765088-93-3
SARS-CoV-2-3CLpro-IN-2
SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases.
2765433-05-2
MAT-POS-e194df51-1
2766185-81-1
SP inhibitor 1
2768834-39-3
SARS-CoV-MPro-IN-2
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 Mpro with an IC50 value of 72.07 nM. The main protease (Mpro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in drug discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19.
2768834-48-4
SARS-CoV-2 Mpro-IN-6
2773516-53-1
Zevotrelvir
2779498-79-0
Mindeudesivir hydrobromide
278603-08-0
NH125
NH125 is a potent and selective eEF-2 kinase inhibitor with an IC50 of 60 nM, and also a potent histidine kinase inhibitor. It shows >125-fold selectivity over PKC, PKA, and CaMKII.
2809363-81-1
HCoV-OC43-IN-1
2816165-02-1
SARS-CoV-2 nsp14-IN-1
2816165-16-7
SARS-CoV-2 nsp14-IN-2
2817810-96-9
SARS-CoV-2-IN-95
2834087-69-1
HIV-1 inhibitor-50
2835511-03-8
GRL-1720
2863657-16-1
RdRP-IN-2
RdRP-IN-2 is a small molecule inhibitor designed to target RNA-dependent RNA polymerase (RdRP), an enzyme essential for the replication of RNA viruses. RdRP-IN-2 inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 µM. By inhibiting RdRP, RdRP-IN-2 aims to disrupt the viral replication process, potentially reducing the viral load and mitigating the severity of infections caused by RNA viruses. This type of inhibitor is valuable in the development of antiviral therapies, especially for diseases caused by viruses with RNA genomes, such as certain coronaviruses, flaviviruses, and other RNA viruses.

※ Please kindly note that our services are for research use only.

Copyright © 2024 BOC Sciences. All rights reserved.